Evidence map›Paper›PMID 31695024›Full record

ArticleCell death & disease2019

MKK3 sustains cell proliferation and survival through p38DELTA MAPK activation in colorectal cancer.

Lorenzo Stramucci, Angelina Pranteda, Arianna Stravato, Carla Azzurra Amoreo, Annarita Pennetti, Maria Grazia Diodoro, Armando Bartolazzi, Michele Milella, Gianluca Bossi

Open access · goldAbstract read
In one paragraph

Article in Cell death & disease, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 32 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Natural products targeting the MAPK-signaling pathway in cancer: overview.Journal of cancer research and clinical oncology · 2024
    Review
  10. Review
  11. Functional Roles of JNK and p38 MAPK Signaling in Nasopharyngeal Carcinoma.International journal of molecular sciences · 2022
    Review
  12. Review
  13. Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. Article
  20. Journal of Cancer · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 2 countries.

Lorenzo StramucciLaboratory of Medical Physics and Expert Systems, Department of Diagnostic Research and Technological Innovation, IRCCS - Regina Elena National Cancer Institute, 00144 Rome, Italy.
Angelina PrantedaLaboratory of Medical Physics and Expert Systems, Department of Diagnostic Research and Technological Innovation, IRCCS - Regina Elena National Cancer Institute, 00144 Rome, Italy.
Arianna StravatoLaboratory of Medical Physics and Expert Systems, Department of Diagnostic Research and Technological Innovation, IRCCS - Regina Elena National Cancer Institute, 00144 Rome, Italy.
Carla Azzurra AmoreoDepartment of Pathology, IRCCS - Regina Elena National Cancer Institute, 00144 Rome, Italy.
Annarita PennettiDepartment of Pathology, IRCCS - Regina Elena National Cancer Institute, 00144 Rome, Italy.
Maria Grazia DiodoroDepartment of Pathology, IRCCS - Regina Elena National Cancer Institute, 00144 Rome, Italy.
Armando BartolazziPathology Research Laboratory, Sant'Andrea Hospital, 00189, Rome, Italy.
Michele MilellaMedical Oncology 1, IRCCS - Regina Elena National Cancer Institute, 00144 Rome, Italy.
Gianluca BossiLaboratory of Medical Physics and Expert Systems, Department of Diagnostic Research and Technological Innovation, IRCCS - Regina Elena National Cancer Institute, 00144 Rome, Italy. gianluca.bossi@ifo.gov.it.ORCID http://orcid.org/0000-0002-2947-1063
Expert System (Italy) · ITIstituti di Ricovero e Cura a Carattere Scientifico · ITCTO Andrea Alesini · ITUniversity of Verona · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Colorectal cancer (CRC) is one of the most common malignant tumors worldwide and understanding its underlying molecular mechanisms is crucial for the development of therapeutic strategies. The mitogen-activated protein kinase-kinase 3 (MKK3) is a specific activator of p38 MAP kinases (p38 MAPKs), which contributes to the regulation of several cellular functions, such as proliferation, differentiation, apoptosis as well as response to drugs. At present, the exact MKK3/p38 MAPK pathway contribution in cancer is heavily debated because of its pleiotropic function. In this work, we retrospectively explored the prognostic and pathobiologic relevance of MKK3 in a cohort of CRC patients and assessed MKK3 molecular functions in a panel of CRC lines and colonocytes primary cultures. We found increased MKK3 levels in late-stage CRC patients which correlated with shorter overall survival. Herein, we report that the MKK3 targeting by inducible RNA interference univocally exerts antitumor effects in CRC lines but not in primary colonocytes. While MKK3 depletion per se affects growth and survival by induction of sustained autophagy and death in some CRC lines, it potentiates response to chemotherapeutic drug 5-fluorouracil (5-FU) in all of the tested CRC lines in vitro. Here, we demonstrate for the first time that in CRC the MKK3 specifically activates p38delta MAPK isoform to sustain prosurvival signaling and that such effect is exacerbated upon 5-FU challenge. Indeed, p38delta MAPK silencing recapitulates MKK3 depletion effects in CRC cells in vitro and in vivo. Overall, our data identified a molecular mechanism through which MKK3 supports proliferation and survival signaling in CRC, further supporting MKK3 as a novel and extremely attractive therapeutic target for the development of promising strategies for the management of CRC patients.

Indexed as

AutophagyCell ProliferationColorectal NeoplasmsDisease-Free SurvivalFemaleFluorouracilGene Expression Regulation, NeoplasticHeterograftsHT29 CellsHumansMaleMAP Kinase Kinase 3Mitogen-Activated Protein Kinase 13Signal TransductionTranscriptional ActivationFluorouracilMAP2K3 protein, humanMAP Kinase Kinase 3Mitogen-Activated Protein Kinase 13

Identifiers

PMID31695024
PMCPMC6834673
OpenAlexW2987288339

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.